白细胞介素2在动脉粥样硬化性心血管疾病抗炎治疗中作用的研究进展
Research progress in the role of interleukin-2 in anti-inflammatory therapy for atherosclerotic cardiovascular disease
孙爽 1崔淯夏 1陈红 1宋俊贤1
作者信息
- 1. 100044 北京大学人民医院心血管内科,心血管转化医学研究中心,急性心肌梗死早期预警和干预北京市重点实验室
- 折叠
摘要
抗炎治疗是降低动脉粥样硬化性心血管疾病(ASCVD)患者心血管残余风险的重要策略.低剂量白细胞介素2 通过增加调节性T细胞和Ⅱ型固有淋巴细胞的数量,提高其功能,从而抑制动脉粥样硬化的发生和发展.随着更多研究证实低剂量白细胞介素 2 在ASCVD抗炎治疗中的有效性和安全性,其有望成为ASCVD抗炎治疗的新选择.
Abstract
Anti-inflammatory therapy is an important strategy to reduce the residual risk of cardiovascular events in patients with atherosclerotic cardiovascular disease.Low dose interleukin-2 inhibits the occurrence and progression of atherosclerosis by increasing both the number and function of regulatory T cells and type 2 innate lymphoid cells.As more studies validate the efficacy and safety of low-dose interleukin-2 in the anti-inflammatory treatment of atherosclerotic cardiovascular disease,it is emerging as a promising new therapeutic option.
关键词
动脉粥样硬化性心血管疾病/白细胞介素2/调节性T细胞/Ⅱ型固有淋巴细胞Key words
Atherosclerotic cardiovascular diseases/Interleukin-2/Regulatory T cells/Type-2 innate lymphoid cells引用本文复制引用
出版年
2024
NETL
NSTL
万方数据